Pembrolizumab: Autoimmune encephalitis: case report.

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA woman [exact age not stated] developed autoimmune encephalitis during treatment with pembrolizumab for lentiginous melanoma [route, dosage, duration of treatment to reaction onset and outcome not stated]. [Extracted from the article]